Slide 1: Exchange filing cover letter - Investor Presentation
October 24, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q2 FY25
Investor Presentation Q2 FY25
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q2 FY25 Highlights
Q2 FY25 | Highlights “The temporary closure of Ankleshwar facility has resulted in delayed servicing of orders, impacting the quarter revenue across geographies. However, the loss of Dr. Yasir Rawjee production has substantially been recovered and we expect H2FY25 to be better than Managing Director
Slide 5: Q2 & H1 FY25 Performance
Q2FY25 Q2 & H1 & FY25 Performance H1 FY25 Performance Revenue EPS EBITDA PAT (In ₹) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) 29.0% 30.4% 28.0% 28.2% 19.9% 20.7% 26.9% 18.3% 18.9% 18.8% 5,954 1,742 9.69 9.69 5,886 1,725 1,650 9.10 1,187 1,188 5,728 1,115 1,446 7.99 979 5,366 Q2 Q3 Q4
Slide 6: P&L Highlights | Q2 & H1 FY25
P&LHighlights P&L Highlights|Q2 Q2&&H1 H1FY25 FY25 Particulars (In ₹ Millions) Q2 FY25 Q1 FY25 QoQ Q2 FY24 YoY H1 FY25 H1 FY24 YoY FY24 Revenue from Operations 5,069 5,886 -13.9% 5,954 -14.9% 10,955 11,738 -6.7% 22,832 Gross Profit 2,817 3,008 -6.3% 3,223 -12.6% 5,825 6,527 -10.8% 12,812 Gross Profi
Slide 7: Healthy Return Indicators
HealthyReturn Strong ReturnIndicators Indicators ROICE (%) Fixed Assets Turnover (Times) Working Capital Days 40% 176 170 166 176 36% 152 34% 33% 3.3 3.4 2.9 28% 2.7 102 107 114 99 89 120 116 136 122 128 -43 -53 -59 -66 FY21 FY22 FY23 FY24 H1 FY25 FY21 FY22 FY23 FY24 H1 FY25 -72 • ROICE is tracking
Slide 8: Financial Performance Track Record
Financial Financial Performance Performance Track Track Record Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 20.6% 31.5% 20.4% 19.7% 30.6% 31.4% 31.1% 3
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance | Generic & CDMO Business
Segment Performance | Generic & CDMO Business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Revenu e In ₹ Milli o n s) 425 5,428 5,354 355 354 5,105 253 4,846 4,739 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 • CDMO business witnessed a decrease in revenue • Gene
Slide 11: Segment Performance | GPL vs Non GPL
Segment Performance | GPL vs Non GPL Non-GPL GPL GPL Non GPL (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 33.4% 37.2% 73.1% 33.5% 31.1% 4,187 68.9% 26.9% 3,954 3,923 2,000 1,963 1,667 66.5% 3,699 1,541 66.6% 62.8% Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q3 FY24
Slide 12: Market and Therapeutic Area Mix
Market andTherapeutic Market and TherapeuticAreaArea Mix Mix Market Mix Therapeutic Area Mix 17% 16% 13% 20% 19% 32% 31% 33% 38% 36% 5% 6% Others 6% 3% 3% 5% 5% 3% Emerging 4% 5% Pain Management Markets 17% 15% 14% 11% 16% Diabetes 83% 84% 87% 80% 81% CNS Regulated Markets CVS 43% 43% 41% 41% 44% Q2
Slide 13: Company Overview
Company Overview fo. G get 7 + yet Glenmark LIFE SCIENCES »)
Slide 14: Global Footprint
Global Footprint • Filed 539 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 108 139 165 10+ 19 125+ 10+ 50+ 22 86 (Brazil) India – Mix of Regulated Number of Number of customers As of September 30, 2
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Milli o n s) North Therapy Europe Japan Brazil Australia ROW Total America 3.3% 3.3% CVS 38 36 4 21 10 37 146 3.0% CNS 38 25 8 16 2 19 108 753 Diabetes 10 5 - 9 - 14 38 2.7% 652 Pain Management 1 2 - 4 1 9 17 Others 78 40 7 36 9 60 230 572 To
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, Quality- compliant focused, manfacturing & compliant R&D infrastructure& R&D infrastructure manufacturing Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA R&D for new
Slide 17: Strategy Going Forward
Strategy Going Forward fo. G get 7 + yet Glenmark LIFE SCIENCES »)
Slide 18: Strategy Growth Levers
Strategy Growth Strategy Growth Levers Levers 1 Gx API Business New product launches Geographical expansion New Growth levers 2 Focus on new markets becoming more regulated Pursue 2nd source opportunities with top generic players CDMO Ramp up Expand into complex API platforms Iron comp
Slide 19: Future Capacity Expansion
Future Capacity Future Capacity Expansion Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of 60KL Pharma Capacity FY26 Brownfield API Dahej Planned addition of 160KL FY26 Phase 1 – 200 KL (Constructi
Slide 20: Thank You
Capex Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN Email: Diwakar.Pingle@in.ey.com Email: Runjhun.Jain1@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA Ho